Fiscal Year Ending March 2026 Financial Summary [Japan GAAP] (Consolidated)

Performance Overview

The consolidated net sales for the fiscal year ending March 2026 were 41,899 billion yen (up 3.4% YoY), maintaining steady growth. Although sales of microbiological testing reagents declined, overseas sales of urine test reagents and fecal blood test reagents increased, and steady performance of products introduced and sold from Toso Corporation contributed to revenue growth. Operating income was 2.919 billion yen (down 2.7%), and ordinary income was 2.844 billion yen (down 11.1%). However, due to the recording of special gains associated with the transfer of stakes in consolidated subsidiaries, net income attributable to owners of parent surged to 3.708 billion yen (up 66.5%), reflecting substantial profit growth.

Financial Position and Dividend Situation

Total assets amounted to 62,657 billion yen, net assets stood at 44,034 billion yen, both increasing YoY, and the equity ratio improved to 70.1%. Regarding dividends, the annual dividend for the fiscal year ending March 2026 is planned at 58 yen per share (up from 53 yen), with a payout ratio of 51.5%. The dividend forecast for the fiscal year ending March 2027 also remains at 58 yen annually.

Earnings Guidance for Fiscal Year Ending March 2027

Sales are projected to be 42,000 billion yen (up 0.2% YoY), operating income 3.070 billion yen (up 5.2%), ordinary income 2.900 billion yen (up 2.0%), and net income attributable to owners of parent 2.070 billion yen (down 44.2%). While expecting increased sales of fecal blood test reagents in overseas markets and ongoing efforts to enhance profitability, a decrease in net income is forecasted due to the reversal of special gains recorded in the previous year.